Mechanisms of trastuzumab resistance and their clinical implications

被引：60
|
作者：
Lan, KH
Lu, CH
Yu, DH
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
来源：
TUMOR PROGRESSION AND THERAPEUTIC RESISTANCE | 2005年 / 1059卷
关键词：
trastuzumab; resistance; ErbB2; breast cancer; PI3K; PTEN;
D O I：
10.1196/annals.1339.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Trastuzumab (Herceptin"') is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.
引用
收藏
页码：70 / 75
页数：6
相关论文
共 50 条
  • [21] Biological mechanisms of resistance to trastuzumab and ways to overcome them: Modern problems of clinical oncology
    Vynnychenko, O.
    Moskalenko, R.
    REGULATORY MECHANISMS IN BIOSYSTEMS, 2024, 15 (02) : 345 - 352
  • [22] Trastuzumab emtansine: mechanisms of action and drug resistance
    Barok, Mark
    Joensuu, Heikki
    Isola, Jorma
    BREAST CANCER RESEARCH, 2014, 16 (02):
  • [23] Trastuzumab (Herceptin®) and breast cancer:: mechanisms of resistance
    Dieras, Veronique
    Vincent-Salomon, Anne
    Degeorges, Armelle
    Beuzeboc, Philippe
    Mignot, Laurent
    De Cremoux, Patricia
    BULLETIN DU CANCER, 2007, 94 (03) : 259 - 266
  • [24] Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
    Waller, Cornelius F.
    Moebius, Julia
    Fuentes-Alburo, Adolfo
    BRITISH JOURNAL OF CANCER, 2021, 124 (08) : 1346 - 1352
  • [25] Biological mechanisms and clinical implications of endocrine resistance in breast cancer
    Giuliano, Mario
    Schiff, Rachel
    Osborne, C. Kent
    Trivedi, Meghana V.
    BREAST, 2011, 20 : S42 - S49
  • [26] Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
    Fang, Pinhao
    Zhou, Jianfeng
    Liang, Zhiwen
    Yang, Yushang
    Luan, Siyuan
    Xiao, Xin
    Li, Xiaokun
    Zhang, Hanlu
    Shang, Qixin
    Zeng, Xiaoxi
    Yuan, Yong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Mechanisms of experimental resistance of Leishmania to miltefosine:: Implications for clinical use
    Perez-Victoria, F. Javier
    Sanchez-Canete, Maria P.
    Seifert, Karin
    Croft, Simon L.
    Sundar, Shyam
    Castanys, Santiago
    Gamarro, Francisco
    DRUG RESISTANCE UPDATES, 2006, 9 (1-2) : 26 - 39
  • [28] HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications
    Miller, MD
    Hazuda, DJ
    DRUG RESISTANCE UPDATES, 2004, 7 (02) : 89 - 95
  • [29] Helicobacter pylori and antimicrobial resistance:: molecular mechanisms and clinical implications
    Gerrits, Monique M.
    van Vilet, Arnoud H. M.
    Kuipers, Ernst J.
    Kusters, Johannes G.
    LANCET INFECTIOUS DISEASES, 2006, 6 (11): : 699 - 709
  • [30] Molecular mechanisms of glucocorticoid resistance hypersensitivity potential clinical implications
    Chrousos, GP
    Castro, M
    Leung, DYM
    Webster, E
    Kino, T
    Bamberger, C
    Elliot, S
    Stratakis, C
    Karl, M
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (02) : S39 - S43
12345